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Abstract 
Background The International Parkinson and Movement Disorders Society criteria 
for mild cognitive impairment in Parkinson’s disease were recently formulated. 
Objectives The aim of this international study was to evaluate the predictive validity 
of the comprehensive (level II) version of these criteria by assessment of their 
contribution to the hazard of Parkinson’s disease dementia. 
Methods Individual patient data were selected from four separate studies on 
cognition in Parkinson’s disease that provided information on demographics, motor 
examination, depression, neuropsychological examination suitable for application of 
level II criteria, and longitudinal follow-up for conversion to dementia. Survival 
analysis evaluated the predictive value of level II criteria for cognitive decline towards 
dementia as expressed by the relative hazard of dementia. 
Results A total of 467 patients were included. The analyses showed a clear 
contribution of impairment according to level II mild cognitive impairment criteria, age 
and severity of Parkinson’s disease motor symptoms to the hazard of dementia. 
There was a trend of increasing hazard of dementia with declining 
neuropsychological performance. 
Conclusions This is the first large international study evaluating the predictive 
validity of level II mild cognitive impairment criteria for Parkinson’s disease. The 
results showed a clear and unique contribution of classification according to level II 
criteria to the hazard of Parkinson’s disease dementia. This finding supports their 
predictive validity and shows that they contribute important new information on the 
hazard of dementia, beyond known demographic and Parkinson’s disease specific 
factors of influence. 
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1 Introduction 
Cognitive deficits have been increasingly recognized as important manifestations of 
Parkinson’s disease (PD). Two important landmarks in this process were the 
formulation of clinical criteria for Parkinson’s Disease Dementia (PDD)1, and more 
recently, clinical criteria for Parkinson’s Disease with Mild Cognitive Impairment (PD-
MCI)2. The International Parkinson and Movement Disorders Society (MDS) PD-MCI 
Validation Study Group was initiated to validate the PD-MCI criteria, starting with the 
evaluation of their prognostic value for the development of PDD3. The underlying 
rationale is that mild cognitive impairment in PD may be regarded as a stage 
between normal cognition and PDD, that is, as “cognitive decline that is not normal 
for age, but with essentially normal functional activities”4. Previous research shows 
that cognitive decline in PD is frequent5,6, can start early in the disease7,8,9 and has a 
heterogeneous presentation10. Some patients rapidly decline towards PDD, and 
others have extended periods of cognitive health, or only minimal impairment. While 
the ability to identify patients with a high risk of rapid cognitive decline is of distinct 
importance for both clinical care and intervention trials, there is a pressing lack of 
validated markers. PD-MCI is a possible clinical marker and can be assessed in an 
abbreviated (level I) or comprehensive (level II) manner according to the MDS PD-
MCI diagnostic criteria2. We conducted a large international study of longitudinal 
individual patient data to evaluate whether level II PD-MCI criteria are a prognostic 
indicator of cognitive decline to dementia. 
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2 Methods 
2.1 Data inclusion 
The formation of the MDS PD-MCI Validation Group has been described earlier3. 
Members contributed individual patient data from either ongoing or completed studies 
in PD. Studies were eligible if they met the following inclusion criteria: 1) longitudinal 
data with at least 75 patients at first measurement and at least 67% participation on 
at least one subsequent visit (as a quality check), 2) known PDD status at follow-up, 
and 3) neuropsychological and disease data to which the level II PD-MCI criteria 
could be applied. The latter required data from studies with standardized 
neuropsychological testing by qualified personnel that included at least two tests per 
each of five cognitive domains (i.e., attention/working memory, executive function, 
language, memory, and visuospatial function) and a measure of gradual cognitive 
decline (a subjective measure provided by either the patient, informant or clinician). 
 
All available demographic and clinical data were retrieved, including information on 
age, gender, years of education, PD duration, global cognitive measures, 
neuropsychological test scores, either Unified Parkinson’s Disease Rating Scale 
(UPDRS) part III11 or MDS UPDRS-III12, Hoehn and Yahr scores13, Mini Mental State 
Exam (MMSE) scores14, and depression. Within included studies, patients with 
disease duration of more than 25 years since PD symptom onset at first 
measurement were excluded to enhance uniformity of the data. Patients were also 
excluded when they had PDD at first measurement. The method used to diagnose 
PDD was allowed to differ across sites and is described below and in table 1. The 
same holds for indicators of depression. 
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2.2 Application of the PD-MCI criteria 
Level II PD-MCI criteria have been described by Litvan et al.2 The two major 
requirements are impairment on comprehensive formal neuropsychological testing 
and gradual cognitive decline, while not fulfilling PDD criteria. 
2.2.1 Impairment on formal neuropsychological testing 
Two tests per cognitive domain were selected in each study database to enhance 
comparability between studies in application of the level II PD-MCI criteria. The 
selection was based on the expert consensus of experienced neuropsychologists 
from all participating centers in the MDS PD-MCI study group. Neuropsychological 
performance on the resulting 10 tests per subject was interpreted against published 
norms where available. Otherwise, normative scores were derived from a local 
control sample using multiple regression techniques correcting for the effects of age, 
gender, and education. Impairment was rated crossing cut-offs of -1SD, -1.5SD and -
2SD from the mean for at least two tests. Patients that did not cross the -1SD level 
for at least two tests were labeled as “no neuropsychological impairment”. Note that 
patients were classified according to their lowest pair of test performances and could 
only belong to one of the four groups.  
2.2.2 Cognitive decline and functional independence 
Cognitive decline reported by the patient, caregiver, and/or clinician is required for 
PD-MCI. Since the criteria do not specify a method to determine this, there were no 
restrictions on the methods used to assess gradual cognitive decline. Although 
functional independence is included in the PD-MCI criteria to rule out PDD, since we 
had already excluded PDD patients, we did not include additional measures of 
functional independence in the application of the PD-MCI criteria. 
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2.2.3 PD-MCI – levels of impairment and its subtypes 
When patients had signs of cognitive decline and impairment on two 
neuropsychological tests, they were categorized as level II PD-MCI and classified 
according to the severity of their impairment as based on different cut-off scores for 
determining impairment. This resulted in four cognitive status groups: one without 
cognitive impairment, and three PD-MCI groups with increasing levels of impairment 
(PD-MCI according to -1, -1.5, and -2SD). Furthermore, the PD-MCI patients were 
classified according to their cognitive domain of impairment when only one domain 
was affected (single domain PD-MCI), and classified as multi-domain PD-MCI if the 




Since 10 neuropsychological tests and a subjective measure of gradual cognitive 
decline were all needed to apply the PD-MCI scoring, we anticipated the need for an 
imputation method. Multiple imputation (MI) is the method of choice for complex 
incomplete data problems15. Advantages are that MI can use the relations between 
the observed measures and preserve them in the imputations, and that it takes 
uncertainty with regard to the missing data into account16. The R statistical software17 
provides a flexible approach to multiple imputation in the mice package15. Twenty 
imputations were created within the original studies using predictive mean matching 
and all variables to be evaluated in further analyses were included in the imputation 
model; an exception was made for derived variables, which were computed based on 
the (imputed) underlying variables (i.e., individual neuropsychological tests were 
imputed, not the cognitive status group classification), and for the time to event, 
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which was replaced by the Nelson Aalen estimate of the cumulative baseline hazard 
as is best practice18. All analyses were performed on the imputed data and were 
pooled using Rubin’s rules19, unless stated otherwise. In short, Rubin’s rules are 
used to derive one overall estimate and variance from the multiple imputations while 
accounting for both the within and between imputation variability. 
2.3.2 Survival analysis 
We used a Cox proportional hazards model with counting process formulation as 
implemented in the R survival package20,21 and rms package22. The event of interest 
was the development of PDD. The time of PD symptom onset was used as the start 
time; the time from PD symptom onset to PDD or censoring as the follow-up time. 
Onset of PDD was estimated to be halfway between the actual observation of PDD 
and the observation prior to that moment, since the exact time of onset is unknown. 
Individuals not developing PDD were censored at their last visit. Use of duration 
since symptom onset as the principal time axis allowed for correction for left-
truncation, which refers to the situation where patients were already at risk of PDD 
before they were included in the study (as in prevalence cohorts). While this was 
necessary due to the structure of the data, it precluded estimation of the effect of 
disease duration. Included predictors were age, gender, years of education, UPDRS-
III, an indicator of depression, and the four categories of cognitive status at first 
measurement. No cognitive impairment was used as the reference group for the 
latter. The rate of PDD was allowed to differ between the original studies by use of 
study site as a stratum variable. Possible non-linearity was examined using restricted 
cubic splines with four knots for all continuous predictors. Proportionality was 
assessed globally and if necessary per covariate by testing for a difference from zero 
of the correlation coefficient between Kaplan Meier transformed survival time and the 
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scaled Schoenfeld residuals. The scaled Schoenfeld residuals were inspected 
visually to detect non-linear patterns possibly invalidating this test. The C statistic 
was used to quantify predictive value, and is defined as the proportion of all possible 
patient pairs for whom the ordering of observed and predicted survival times is 
concordant. A bootstrapping approach using 200 samples was used to estimate 
slope shrinkage and corrected Nagelkerke R2 as suggested in Harrell et al.23. For the 
C statistics, slope shrinkage and Nagelkerke R2 estimates, their median over 
imputations was obtained since Rubin’s rules do not apply to their distributions.  
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3 Results 
3.1 Data inclusion 
Twenty-three validation study group sites contributed individual patient data from 24 
studies. Figure 1 schematically displays the inclusion process. A total of 467 patients 
from four large longitudinal cohort studies fulfilled the inclusion criteria. These studies 
will be referred to as the AZSAND cohort, the CARPA cohort7, the NZBRI cohort24, 
and the Toronto cohort25. The AZSAND cohort is part of the Arizona Study of Aging 
and Neurodegenerative Disease26. Cohort details are summarized in table 1. Both 
open and closed cohorts and both incident and prevalent cohorts were followed. 
Follow-up length, frequency and intervals differed between the studies. PD was 
diagnosed according to standard criteria32,33. Neuropsychological scores in the 
CARPA, NZBRI, and Toronto cohort, were adjusted for age, education, and/or 
gender where applicable, based on published norms. In the AZSAND cohort, 
normative scores were derived from a sample of 708 non-PD community volunteers. 
All anticipated demographic and clinical information was available in all four centers 
except for the Hoehn and Yahr scores. Either UPDRS III11 or MDS UPDRS III12 was 
used to assess motor function and comparable scores on the scale of the UPDRS-III 
were derived using conversion guidelines34. These will further be referred to as 
UPDRS-III* to reflect the mixed nature. However, the patients in the ASZAND cohort 
were mostly assessed in practically defined off state, whereas the others were mostly 
assessed in on state. Furthermore, PDD classification differed across centers. MDS 
PDD criteria1 were used in the NZBRI, Toronto, and AZSAND cohort, with additional 
use of DSM-IV criteria35 in the latter. The CARPA study used a Mini Mental State 
Exam14 cut-off as used in the Dubois screening criteria36 (<26) in combination with 
the cognitive items of the Functional Independence Measures (FIM)37 (≥1 item with a 
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score ≤5), or an MMSE score below 21 regardless of functional impairment. The 
available information on depression differed across centers as well, as indicated in 
table 1. These measures were all summarized to either indicate presence of absence 
of depression to enable shared analyses using all available data. Detailed 
information on the neuropsychological examinations is available table 2. 
 
3.2 Missing values 
The percentage of missing values in age, gender, years of education and PD 
symptom duration ranged from 0 to 1%. Gradual cognitive decline had 2% missing 
values, the UPDRS-III* 6%, and indicators of depression were missing in 9%. One 
percent had a missing attention test, versus 2% for visuospatial and executive 
function respectively, 10% for memory, and 16% for language. PD-MCI depends on 
multiple measures and was missing in 22%. Since only a small portion of the 
neuropsychological tests is missing and their mutual relations are strong, the 
conditions are such that multiple imputation is expected to perform well. 
 
3.3 Individual patient data descriptives 
Descriptive statistics are shown in table 3. Included patients (n=467) had a mean age 
of 69 years, male predominance (63%), a median duration since PD symptom onset 
of 4 years and a median UPDRS-III* score of 20. Fifteen percent had a positive 
indicator for depression. Forty percent of the patients had neuropsychological 
impairment, roughly equally divided over the PD-MCI groups. Regarding PD-MCI 
subtypes, the majority of patients (92%) had multi-domain impairment. The other 8% 
were scattered over the single-domains. To provide an overview of the available data 
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over time, online supplementary figure 1 shows the distribution of observation 
periods. 
 
Table 3 shows that 69 patients developed PDD during follow-up (14.3%). Only 6.4% 
of patients without any cognitive impairment at first measurement developed PDD, 
progressively increasing to 50.0% of the PD-MCI group fulfilling the -2SD cut-off on 
first neuropsychological evaluation. Further examination of the involvement of 
individual cognitive domains in PD-MCI classification revealed that each of the five 
domains was commonly impaired and that their association with conversion to PDD 
was heterogeneous. Details are provided in online supplementary table 1.  
 
Note that in this section on descriptive statistics, important characteristics of the data, 
among which the interrelation between covariates, left truncation and censoring, 
cannot be taken into account. However, the survival analyses reported in the 
following section take these aspects into account.  
 
3.4 Survival analyses 
A Cox model including all covariates and stratified by the study sites met the 
proportionality assumption (chi-square 11.55, df 8, p-value 0.17). Therefore, the 
covariate effects did not significantly change over time since PD symptom onset. 
Furthermore, all nonlinear terms were not significant (chi-square 10.90, df 6, p-value 
0.09) and left out of the model. The results for the final model are shown in table 4 
and online supplementary figure 2. The hazard of PDD was higher with increasing 
age and UPDRS-III* score. Gender, years of education and the indicator of 
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depression had no significant effect. PD-MCI below the -1.5SD cut-off clearly raised 
the hazard of PDD.  
 
As a measure of the predictive value of the survival model, the median observed C 
statistic was 0.85, which means that in 85% of the possible paired patient 
comparisons, prediction and outcome are concordant. (i.e., the predicted time to 
event was shorter for the one first developing PDD). The median bootstrap corrected 
Nagelkerke R2 was 0.28. The median slope shrinkage estimate was 0.86, indicating 
that an estimated 14% of the model fit was due to overfitting. 
 
To increase insight into the relative contribution of the individual predictors to the 
hazard of PDD, bootstrap corrected R2 values were derived for different sub-models. 
A model stratified on study site and including only age explained 10.3 % of the 
variance. Adding gender, years of education, UPDRS* and an indicator of depression 
increased this to 12.4%. PD-MCI bridges the gap to 28.0%. Age and PD-MCI 
therefore clearly have the largest contribution. 
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4 Discussion 
We found level II MDS PD-MCI to be clearly related to the hazard of PDD after 
controlling for demographic characteristics, severity of PD and indicators of 
depression. This constitutes a new contribution to the PD-MCI literature, adds to the 
validation process of the level II MDS PD-MCI criteria, and thereby supports their 
application. In more detail, the analyses showed an increase in hazard with 
decreasing performance on neuropsychological examination, while correcting for 
possible confounders. This can be interpreted as a relative increase in the rate of 
conversion to PDD. The results indicated that this relative difference was constant 
over time, that is, the relative difference between cognitively healthy patients and PD-
MCI patients at each consecutive time point since symptom onset was the same. As 
an example, the relative hazard to develop PDD for patients in the -1.5 to -2 SD 
group was, at any time since PD symptom onset, estimated to be approximately 3.5 
times higher than for the cognitively healthy patients. This effect is comparable to the 
effect of an age difference of approximately 14 years or an increase in UPDRS-III* 
score of 37 points. The increase in hazard with increasing age and increasing PD 
severity is consistent with literature reviews by Aarsland and Kurtz38 and Litvan et 
al.4.  
 
Furthermore, the pattern of increase in hazard with each successive degree of 
neuropsychological impairment gives new insight into the use of cut-offs for the level 
II criteria when predicting PDD. Namely, a selection of one cut-off loses important 
information, due to grouping of patients with a different hazard of PDD. While the 
ease of use of one cut-off is evident, the current study was able to show that 
progressive impairment keeps adding to the hazard of PDD. This is in line with the 
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view of mild cognitive impairment as a stage on the continuum between normal 
cognition and PDD. Regarding clinical relevance, the view of the MDS PD-MCI 
validation study group is that impairment beyond the -1.5SD cut-off represents 
clinically meaningful decline. The -1.5 to -2 SD group, with an estimated 3.5 times 
increase in the hazard of PDD when compared to the normal cognition group, is also 
deemed to be sufficiently far from the development of PDD to be a meaningful 
subgroup. These patients could for instance be an interesting sub-population for 
medication trials aiming to halt progression of cognitive decline. 
 
Concerning the PD-MCI sub-classification in single- and multi-domain impairment, 
the groups of single-domain impairment were too small to provide useful statistical 
inference. Only 8% had single domain impairment, without any meaningful pattern 
over the 5 cognitive domains. This is in agreement with an earlier study on the level II 
PD-MCI criteria in an individual PD cohort39. These findings may reflect widespread 
cognitive deficits or lack of sufficient specificity among current cognitive test 
measures, or could result from a bias towards multiple domain impairment in the 
MDS PD-MCI criteria. 
 
There are several strengths in the current study. First, the predictive effect of level II 
PD-MCI was assessed over an extensive follow-up period. Second, it is the first 
study to uniformly apply the level II PD-MCI criteria in a varied and large international 
sample of PD patients. As specifically allowed in the MDS PD-MCI criteria, patients 
were examined with a variety of instruments reflecting the variability that exists 
across different international centers. Furthermore, a broad spectrum of disease 
duration was available with first assessments on patients ranging from 0 to 23 years 
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since PD symptom onset. Under these heterogeneous circumstances, level II PD-
MCI strongly contributed to the hazard of PDD. A downside to the approach favoring 
external validity is the limited comparability of the used measurement instruments. 
Each study followed their own local procedures and this resulted in a variety of 
applied measures, with little overlap. This precluded evaluation of the prognostic 
value of individual measures in the aggregated data, and it necessitated expert 
consensus based selection from the available measures to rate PD-MCI. The 
difference in study designs also impeded easy interpretation of the PD-MCI 
prevalence values and resulted in different operationalizations of conversion to PDD. 
Future prospective, large-scale studies could be designed with these issues in mind. 
 
A limitation of the study is the small number of conversions to PDD and the limited 
number of studies, which impeded analyses of possibly important interaction effects, 
inter-study variability, and the derivation of time to PDD conversion estimates for 
possible clinically meaningful subgroups. Consequently, it precludes direct 
generalization of the results to the individual patient level, since this should take the 
between center variability into account. Furthermore, the effect of duration since 
symptom onset could not be estimated, since it was needed as the time axis to 
correct for the left-truncated structure of the data due to the inclusion of prevalence 
cohorts. A further limitation is the possibility of informative censoring, also known as 
attrition bias. In any longitudinal cohort study design, patients returning for follow-up 
assessments may differ from those who do not (e.g., depending on patient health 
and its relation to the incentive to participate). Informative censoring denotes the 
situation where leaving the study is not independent of the study outcome. In the 
current setting, lacking information on mortality as a potentially important competing 
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risk renders the analyses prone to violation of the assumption of non-informative 
censoring. In other words, when mortality and PDD share a biological cause, 
censoring due to mortality is informative of the hazard of PDD. Unfortunately, the 
current data cannot be used to estimate this possible influence and there is no 
research on this relation in PD. Informative censoring in general illustrates a 
challenge of longitudinal studies in an advancing neurodegenerative disorder and 
cautions that study samples may be less representative over time, leading to biased 
estimates*.  
 
Our results represent a basic validation of level II MDS PD-MCI as a risk factor for 
PDD, but are not exhaustive, given the multiple ways that level II MDS PD-MCI 
criteria can be applied. The available data directed the focus to detection of cognitive 
impairment by means of normative neuropsychological test scores. However, the 
criteria can also be fulfilled by decline on serial cognitive testing or decline from 
premorbid level. While these options are specifically mentioned in the criteria, their 
operationalization is not yet clearly defined. In general, the multitude of available 
options in application of the PD-MCI criteria achieves a greater flexibility for their use 
but that can also be a potential limitation. Differences in allo ed measures, cut-off 
scores and definitions of impairments should lead to caution when comparing 
different applications of the criteria. We recommend that future research further 
operationalizes the PD-MCI criteria across diverse populations. 
                                                      
*
 Unless the informative censoring is a competing risk that can be analyzed as such 
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Figures and tables 
Figure 1 
Title: Flowchart showing the data inclusion process 
 
Online supplementary figure 1 
Title: Distribution of the observation periods since onset of PD symptoms 
Legend: Each line represents the observation period of an individual. The x-axis 
shows duration since PD symptom onset in years. Centers are color-coded: AZSAND 
(red), CARPA (dark-blue), NZBRI (light-blue), and Toronto (orange). (n=470). 
Patients not developing PDD are shown on the left side and patients developing PDD 
at the right. 
 
Online supplementary figure 2 
Title: Effects of the predictors on the hazard of PDD 
Legend: Estimated effects of the predictors are displayed when all other predictors 
are fixed at their median value (age 69, 14 years of education, and a UPDRS-III* 
score of 20). The y-axis shows the log Relative Hazard with respect to these values. 
The x-axis is on the scale of the predictors. A log Relative Hazard of 0 equals no 
effect; a positive slope corresponds to increasing hazard. 95% confidence intervals 
are shown in gray. Note the change of scales for the axis over plots. 
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Table 1. Cohort details of the included studies 
Cohort AZSAND (n = 101) CARPA (n = 112) NZBRI (n = 136) Toronto (n = 118) 









(range in years) 
Yearly 
(range: 0.5 to 6.0) 
  
0,3,5, and 8 years 
(range: 1.4 to 9.0) 
baseline + 
approximately 2-yearly 
up to 6 years 
(range: 0.8 to 6.2) 
 
0,1, and 2 years 
(range: 0.5 to 3.3) 
PD criteria UKPDS Brain Bank Gelb  UKPDS Brain Bank UKPDS Brain Bank 
PDD criteria MDS PDD and 
DSM-IV 
Based on MMSE 
and FIM* 
MDS PDD MDS PDD 


















UPDRS I item I 
PDQL27 item 31 
and 34 
 
PDQ-3928 item 32 & 
CDR29 memory items 
 






Indicator of depression 
(absent/present) 
 use of 
antidepressants 
HADS depression 
subscore ≥ 11 30 
NPI depression subscale 
total score (frequency x  
severity) ≥ 4 31 
Geriatric Depression 
Scale 15 score ≥ 5 30 
The table shows the cohort types, diagnostic criteria, reference used for evaluation of neuropsychological performance and the 
measures of subjective cognitive decline for each of the studies. Abbreviations: CDR = Clinical Dementia Rating; GDS15 = 
Geriatric Depression Scale 15, HADS = Hospital Anxiety and Depression Scale, NBI = Neurobehavioral Signs and Symptoms 
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Abbreviated Inventory; NPI = Neuropsychiatric Inventory, UPDRS = Unified Parkinson's Disease Rating Scale; PDQ-39 = 
Parkinson's Disease Questionnaire 39; PDQL = Parkinson's Disease Quality of Life Questionnaire. 
*Refer to the main text for more details 
**References are provided for the scales not further mentioned in the text. 
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Table 2. Tests that were used for Level II MDS PD-MCI analyses. 









Tower of London total 
moves score 
RAVLT delayed recall 
RBMT delayed recall 
JOLO 
GIT Legkaarten* 




Digit Ordering Test 
WAIS-III Digit Span total 
Stroop interference 
(DKEFS) 
Trail making test B 
CVLT II long delayed 
recall 
RCF delayed recall 
JOLO 
RCF copy 
AZSAND Boston Naming 
Test 
Category fluency 
WMS-R Digit Span 
backward 
WMS-R Digit Symbol 
Stroop interference 
Letter fluency 
RAVLT delayed recall 









WAIS-III Letter Number 
Sequencing 






CVLT II long delayed 
recall 
RCF delayed recall 
JOLO 
RCF copy 
All obtained scores were normative scores. For tests with more than one main outcome available, such as the Tower of London, 
the specific score used in mentioned. Note that, based on expert consensus, the same test can appear in multiple domains and 
more general tests can appear outside of their primary domain. This reflects difference in availability between individual studies. 
Therefore, semantic fluency can be the best available language test and the Stroop interference can appear in both the attention 
and executive domain.  
* Dutch; this is a tangram-like visuospatial subtest of the Dutch Groningen Intelligence Test 
Abbreviations: CVLT = California Verbal Learning Test, DKEFS = Delis–Kaplan Executive Function System, JOLO = Judgment of 
Line Orientation Test, MWCST = Modified Wisconsin Card Sorting Test, RAVLT = Rey Auditory Verbal Learning Test, RBMT = 
Rivermead Behavioral Memory Test, RCF = Rey Complex Figure, WAIS-R/III= Wechsler Adult Intelligence Scale version 
Revised/III, WMS-R = Wechsler Memory Scale-Revised. 
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Table 3. Descriptive statistics at first measurement and conversion to PDD 


















68.7 (8.8;  
32-86) 
Gender, male (frequency, %)  66 (65.3) 59 (52.7) 87 (64.0) 81 (68.6) 293 (62.7) 
Education, years (mean, SD; 
range) 
 15.5 (2.6;  
8-23) 
11.6 (2.5;  
7-18) 
13.0 (2.9;  
8-20) 
15.9 (2.4;  
8-20) 
14.0 (3.1;  
7-23) 










PD symptom duration, years 
(median, IQR; range) 


















20 (13-28;  
1-69)  
Positive indicator of depression 
(frequency, %),  
 29 (28.7) 10 (8.9) 28 (20.6) 2 (1.7) 69 (14.8) 
PD-MCI count (frequency, %) no impairment 
-1 to -1.5SD 






















Conversion to PDD by cognitive 
classification (frequency / n, %) 
no impairment 
-1 to -1.5SD 


















18 / 280 (6.4) 
8 / 67 (11.9) 
12 / 58 (20.7) 
31 / 62 (50.0) 
Person years of follow-up by 
cognitive classification (years, 
years per event) 
no impairment 
-1 to -1.5SD 
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Table 4: Multivariate Cox proportional hazards model evaluating the hazard of PDD 
 β SE 95% CI HR (eβ) z-statistic p 
Age (per year) 0.09 0.02  (0.05 ; 0.13) 1.09 4.36 <0.005 
Gender (male) 0.26 0.29 (-0.32 ; 0.83) 1.29 0.88 0.38 
Years of education 0.00 0.05 (-0.11 ; 0.10) 1.00 -0.06 0.95 
PD-MCI-1 to -1.5SD 0.71 0.45 (-0.18 ; 1.59) 2.02 1.56 0.12 
PD-MCI-1.5 to -2SD 1.24 0.45  (0.37 ; 2.11) 3.46 2.78 <0.01 
PD-MCI below -2SD 2.42 0.35  (1.73 ; 3.11) 11.3 6.89 <0.005 
UPDRS-III* 0.03 0.01  (0.01 ; 0.06) 1.03 2.49 0.01 
Depression indicator -0.22 0.47 (-1.14 ; 0.70) 0.80 -0.47 0.64 
The overall model chi-square (df 8) was 97.5 (p < 0.005). The reference categories were female and no cognitive impairment. For 
continuous variables, hazard ratios are expressed per unit difference on their scale of measurement (years and UPDRS-III* points 
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Title: Flowchart showing the data inclusion process  
Figure 1  
124x125mm (300 x 300 DPI)  
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 Title: Distribution of the observation periods since onset of PD symptoms Legend: Each line represents 
the observation period of an individual. The x-axis shows duration since PD symptom onset in years. Centers 
are color-coded: AZSAND (red), CARPA (dark-blue), NZBRI (light-blue), and Toronto (orange). (n=470). 
Patients not developing PDD are shown on the left side and patients developing PDD at the right.  
online supplementary figure 1  
202x135mm (300 x 300 DPI)  
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Title: Effects of the predictors on the hazard of PDD. Legend: Estimated effects of the predictors are 
displayed when all other predictors are fixed at their median value (age 69, 14 years of education, and a 
UPDRS-III* score of 20). The y-axis shows the log Relative Hazard with respect to these values. The x-axis 
is on the scale of the predictors. A log Relative Hazard of 0 equals no effect; a positive slope corresponds to 
increasing hazard. 95% confidence intervals are shown in gray. Note the change of scales for the axis over 
plots.  
online supplementary figure 2  
113x61mm (300 x 300 DPI)  
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Online supplementary table 1: Domain involvement in PD-MCI 
Domain 
involved in  
PD-MCI 
PD-MCI group Number of 
cases 











   
no -1 to -1.5SD 42 (62.7%) 5 129.1 25.8 
no -1.5 to -2SD 36 (62.1%) 8 102.6 13.5 
no below -2SD 44 (71.0%) 20 99.8 4.9 
yes -1 to -1.5SD 25 (37.3%) 3 125.8 39.3 
yes -1.5 to -2SD 22 (37.9%) 4 114.0 28.5 
yes below -2SD 18 (29.0%) 11 38.4 3.5 
Attention/working memory impairment 
 
no -1 to -1.5SD 32 (47.8%) 1 117.0 102.1 
no -1.5 to -2SD 40 (69.0%) 7 133.4 20.3 
no below -2SD 43 (69.4%) 19 88.0 4.7 
yes -1 to -1.5SD 35 (52.2%) 7 137.9 19.7 
yes -1.5 to -2SD 18 (31.0%) 5 83.2 16.6 
yes below -2SD 19 (30.6%) 12 50.1 4.0 
Memory impairment 
   
no -1 to -1.5SD 22 (32.8%) 0 71.8 na 
no -1.5 to -2SD 24 (41.4%) 3 91.2 30.4 
no below -2SD 19 (30.6%) 10 43.4 4.2 
yes -1 to -1.5SD 45 (67.2%) 8 183.1 22.2 
yes -1.5 to -2SD 34 (58.6%) 9 125.3 14.6 
yes below -2SD 43 (69.4%) 21 94.8 4.5 
Executive function impairment 
  
no -1 to -1.5SD 38 (56.7%) 5 159.8 30.6 
no -1.5 to -2SD 35 (60.3%) 6 155.0 25.8 
no below -2SD 32 (51.6%) 9 79.1 8.3 
yes -1 to -1.5SD 29 (43.3%) 3 95.1 31.7 
yes -1.5 to -2SD 23 (39.7%) 6 61.6 11.1 
yes below -2SD 30 (48.4%) 22 59.1 2.7 
Visuospatial function impairment 
  
no -1 to -1.5SD 42 (62.7%) 7 177.3 24.5 
no -1.5 to -2SD 33 (56.9%) 8 127.7 16.0 
no below -2SD 26 (41.9%) 12 71.0 5.8 
yes -1 to -1.5SD 25 (37.3%) 1 77.6 77.6 
yes -1.5 to -2SD 25 (43.1%) 4 88.8 25.1 
yes below -2SD 36 (58.1%) 19 67.2 3.5 
For each PD-MCI group, the comparison between involvement/no involvement of the 
specific cognitive domains in the impairment is shown. Therefore. these are five different 
dichotomizations of the data. The total number in each group is shown (e.g. on the first row: 
42 patients had no language impairment and PD-MCI with impairment between -1 and -
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1.5SD, which represents 62.7% of the total of 42 + 25 = 67 patients in the -1 to -1.5SD PD-
MCI group. Furthermore, the number of conversions to PDD, total person years follow-up, 
and total years follow-up per event are shown. 
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